Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window [Seeking Alpha]
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: Seeking Alpha
CRBP will now focus on unmet needs in 2nd-line head and neck squamous cell carcinoma and cervical cancer, where early data shows superior ORRs. The company has a solid cash runway through Q2 2027 and upcoming catalysts, including an FDA meeting in H2 2025 and potential phase 3 trial initiations in 2026. Risks for CRBP include competitive pressures for both CRB-701 and CRB-601, as well as the need to replicate early efficacy and safety in larger trials. Moment Makers Group/iStock via Getty Images The last time I spoke about Corbus Pharmaceuticals Holdings, Inc. CRBP ), it was in a Seeking Alpha article entitled "Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025." At that time, I More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period fo
Show less
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lowered by analysts at Royal Bank Of Canada from $55.00 to $53.00. They now have an "outperform" rating on the stock.MarketBeat
- Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Corbus Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Corbus Pharmaceuticals Announces Pricing of Public OfferingGlobeNewswire
- Corbus Pharmaceuticals Announces Proposed Public OfferingGlobeNewswire
CRBP
Earnings
- 11/12/25 - Miss
CRBP
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- 11/12/25 - Form SCHEDULE
- CRBP's page on the SEC website